Measuring Survival Benefit in Health Technology Assessment in the Presence of Nonproportional Hazards
Author:
Funder
Pfizer Inc.
Publisher
Elsevier BV
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference34 articles.
1. NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation With Patient-Level Data;Latimer,2011
2. Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide;Latimer;Med Decis Making,2013
3. Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach;Bagust;Med Decis Making,2014
4. Response to “survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach” by Bagust and Beale;Latimer;Med Decis Making,2014
5. Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials;Trinquart;J Clin Oncol,2016
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma;Journal of Comparative Effectiveness Research;2023-08
2. Direct Incorporation of Expert Opinion into Parametric Survival Models to Inform Survival Extrapolation;Medical Decision Making;2023-01-16
3. Clinical effectiveness reporting of novel cancer drugs in the context of non-proportional hazards: a review of nice single technology appraisals;International Journal of Technology Assessment in Health Care;2023
4. Restricted Mean Survival Time Analysis to Estimate SGLT2i–Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan;JAMA Network Open;2022-12-15
5. The impact of statistical properties of incremental monetary net benefit and incremental cost-effectiveness ratio on health economic modeling choices;Expert Review of Pharmacoeconomics & Outcomes Research;2022-11-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3